Gilead targets hep B in half a billion dollar deal with Precision BioSciences - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Gilead targets hep B in half a billion dollar deal with Precision BioSciences, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Gilead targets hep B in half a billion dollar deal with Precision BioSciences
link : Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gemma Jones

14th September 2018

Biopharma looks to genome editing platform to discover hepatitis B cure

Following its success in curing hepatitis C with therapies such as Sovaldi and Harvoni, Gilead is now enlisting a new partner in the fight against hepatitis B (HBV).

Inking a collaboration deal that would be worth half a billion dollars with genome editing specialists Precision Biosciences, Gilead is aiming to develop a cure for HBV, which is proving more difficult to eliminate than hep C.

Continue reading....

Thus articles Gilead targets hep B in half a billion dollar deal with Precision BioSciences

that is all articles Gilead targets hep B in half a billion dollar deal with Precision BioSciences This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Gilead targets hep B in half a billion dollar deal with Precision BioSciences the link address https://newsaninpiration.blogspot.com/2018/09/gilead-targets-hep-b-in-half-billion.html

Tweet

Subscribe to receive free email updates: